SPOTLIGHT: Roche buys Ventana shares


It's in the bag. Roche has officially acquired 70.5 percent of Ventana's shares, enough to wrap up the acquisition. But Roche has extended its $3.4 billion tender offer to February 15 in an attempt to nab more shares, because if it can boost that percentage above 90, the closing will be easier to manage. Last month, Roche upped its offer to $89.50 per share from $75. Report

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.